These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 38844134)
41. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463 [TBL] [Abstract][Full Text] [Related]
42. Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer. Yuan W; Deng D; Jiang H; Tu C; Shang X; He H; Niu R; Dong J Cancer Immunol Immunother; 2019 Feb; 68(2):257-268. PubMed ID: 30406373 [TBL] [Abstract][Full Text] [Related]
43. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569 [TBL] [Abstract][Full Text] [Related]
44. FOXA1/UBE2T Inhibits CD8 Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180 [TBL] [Abstract][Full Text] [Related]
45. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497 [TBL] [Abstract][Full Text] [Related]
46. Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer. Ma G; Liang Y; Chen Y; Wang L; Li D; Liang Z; Wang X; Tian D; Yang X; Niu H Mol Cancer Res; 2020 Feb; 18(2):324-339. PubMed ID: 31672701 [TBL] [Abstract][Full Text] [Related]
47. Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497/PD-L1 pathway. Xu YJ; Zhao JM; Gao C; Ni XF; Wang W; Hu WW; Wu CP Cell Signal; 2021 Oct; 86():110095. PubMed ID: 34320370 [TBL] [Abstract][Full Text] [Related]
48. Regulation of PD-L1 expression in the tumor microenvironment. Yi M; Niu M; Xu L; Luo S; Wu K J Hematol Oncol; 2021 Jan; 14(1):10. PubMed ID: 33413496 [TBL] [Abstract][Full Text] [Related]
49. Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer. Sun L; Patai ÁV; Hogenson TL; Fernandez-Zapico ME; Qin B; Sinicrope FA Oncogene; 2021 Aug; 40(32):5105-5115. PubMed ID: 34193942 [TBL] [Abstract][Full Text] [Related]
51. Breast cancer cells promote CD169 Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052 [TBL] [Abstract][Full Text] [Related]
52. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8 Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170 [TBL] [Abstract][Full Text] [Related]
53. PPARα Promotes Cancer Cell Glut1 Transcription Repression. You M; Jin J; Liu Q; Xu Q; Shi J; Hou Y J Cell Biochem; 2017 Jun; 118(6):1556-1562. PubMed ID: 27918085 [TBL] [Abstract][Full Text] [Related]
54. Mechanisms Controlling PD-L1 Expression in Cancer. Cha JH; Chan LC; Li CW; Hsu JL; Hung MC Mol Cell; 2019 Nov; 76(3):359-370. PubMed ID: 31668929 [TBL] [Abstract][Full Text] [Related]
55. Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1. Ge J; Wang J; Xiong F; Jiang X; Zhu K; Wang Y; Mo Y; Gong Z; Zhang S; He Y; Li X; Shi L; Guo C; Wang F; Zhou M; Xiang B; Li Y; Li G; Xiong W; Zeng Z Cancer Res; 2021 Oct; 81(19):5074-5088. PubMed ID: 34321242 [TBL] [Abstract][Full Text] [Related]
56. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737 [TBL] [Abstract][Full Text] [Related]
57. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1. Ibrahim AA; Fujimura T; Uno T; Terada T; Hirano KI; Hosokawa H; Ohta A; Miyata T; Ando K; Yahata T Front Immunol; 2024; 15():1365894. PubMed ID: 38779680 [TBL] [Abstract][Full Text] [Related]
58. Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling. Chen Q; Zhuang S; Hong Y; Yang L; Guo P; Mo P; Peng K; Li W; Xiao N; Yu C Oncogene; 2022 Mar; 41(10):1421-1433. PubMed ID: 35027670 [TBL] [Abstract][Full Text] [Related]
59. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Chen N; Fang W; Lin Z; Peng P; Wang J; Zhan J; Hong S; Huang J; Liu L; Sheng J; Zhou T; Chen Y; Zhang H; Zhang L Cancer Immunol Immunother; 2017 Sep; 66(9):1175-1187. PubMed ID: 28451792 [TBL] [Abstract][Full Text] [Related]
60. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. Stein A; Simnica D; Schultheiß C; Scholz R; Tintelnot J; Gökkurt E; von Wenserski L; Willscher E; Paschold L; Sauer M; Lorenzen S; Riera-Knorrenschild J; Depenbusch R; Ettrich TJ; Dörfel S; Al-Batran SE; Karthaus M; Pelzer U; Waberer L; Hinke A; Bauer M; Massa C; Seliger B; Wickenhauser C; Bokemeyer C; Hegewisch-Becker S; Binder M J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34315821 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]